(ANNX) Annexon - Ratings and Ratios

Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical company pioneering therapies for inflammatory-related diseases. Its pipeline focuses on neurodegenerative and autoimmune disorders, leveraging its expertise in targeting the classical complement pathway. The companys lead candidate, ANX005, is a full-length monoclonal antibody in a Phase 3 trial for Guillain-Barré Syndrome (GBS), a rare autoimmune disorder. ANX005 has also completed a Phase 2 trial for Huntingtons disease (HD), demonstrating potential in neurodegenerative conditions, and is currently in a Phase 2 trial for amyotrophic lateral sclerosis (ALS). Additionally, Annexon is advancing ANX007, an antigen-binding fragment (Fab), in a Phase 3 program for geographic atrophy, a form of advanced dry age-related macular degeneration (AMD). The company is also developing ANX1502, an oral small molecule inhibitor, in Phase 1 trials for autoimmune indications, and ANX009, a C1q-blocking Fab, in a Phase 1 trial for lupus nephritis. Founded in 2011, Annexon is headquartered in Brisbane, California.

Annexons clinical-stage pipeline reflects its strategic focus on addressing unmet medical needs in inflammatory and autoimmune diseases. ANX005s progression to Phase 3 for GBS highlights its potential to become a first-in-class treatment for this acute neurological condition. The companys broader pipeline, including ANX007 for geographic atrophy and ANX009 for lupus nephritis, underscores its commitment to targeting complement-mediated diseases. With a robust research and development framework, Annexon aims to deliver innovative therapies for patients with limited treatment options.

Based on the provided and , the 3-month forecast for Annexon, Inc. (NASDAQ:ANNX) suggests the following: - Technical Outlook: The stock is currently trading below its 20-day and 50-day simple moving averages (SMA), with a last price of $2.64 compared to SMA 20 at $3.08 and SMA 50 at $4.07. The average true range (ATR) of 0.27 indicates moderate volatility. - Fundamental Outlook: With a market cap of $301.66M and a price-to-book (P/B) ratio of 0.92, the stock is undervalued relative to its book value. The return on equity (RoE) of -35.44% reflects the companys ongoing R&D investments and clinical trial expenses. - 3-Month Forecast: The stock may face near-term downside pressure due to its current position below key moving averages. However, positive clinical trial data or regulatory advancements could act as catalysts for a potential rebound. Support levels may form near $2.37 (50% retracement of recent highs), while resistance is expected at $3.50 (SMA 20). Traders should monitor trial updates and broader market sentiment for biotechnology stocks.

Web URL: https://www.annexonbio.com